The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls

Biological Psychiatry
A BroocksT Sunderland

Abstract

There is evidence from animal and human experiments that learning and memory come under the separate influence of both cholinergic and serotonergic pathways. We were interested in learning whether serotonergic drugs could attenuate or exacerbate the memory-impairing effects of anticholinergic blockade in humans. The selective serotonin 5-HT3 receptor antagonist ondansetron (0.15 mg/kg i.v.) and the serotonergic agent m-chlorophenylpiperazine (m-CPP; 0.08 mg/kg i.v.) were administered in combination with the anticholinergic agent scopolamine (0.4 mg PO) and compared to scopolamine alone in 10 young, healthy volunteers. Testing occurred on three separate days. As expected, i.v. administration of scopolamine induced significant impairments in episodic memory and processing speed; however, these scopolamine-induced cognitive deficits were not attenuated by pretreatment with i.v. ondansetron (0.15 mg/kg), nor were they exacerbated by administration of i.v. m-CPP (0.8 mg/kg) in addition to scopolamine; however, administration of i.v. m-CPP was followed by a significant increase of self-rated functional impairment, altered self-reality, and dysphoria ratings, and scopolamine's effect on pupil size was potentiated. Together, these resu...Continue Reading

References

Mar 1, 1992·Pharmacology & Toxicology·B Costall, R J Naylor
Jan 1, 1992·British Journal of Anaesthesia·D Russell, G N Kenny
Sep 1, 1992·Journal of Gerontology·R D NebesC F Reynolds
Dec 1, 1991·Biological Psychiatry·R S Kahn, S Wetzler
Apr 1, 1990·Pharmacology, Biochemistry, and Behavior·J M BarnesM B Tyers
Jan 1, 1990·Pharmacology & Therapeutics·B CostallM B Tyers
Jun 1, 1988·British Journal of Pharmacology·A ButlerM B Tyers
Jan 1, 1987·Psychopharmacology·J F Flood, A Cherkin
Aug 1, 1969·Planta medica·F Newcombe, B A Patel
Mar 1, 1980·Archives of General Psychiatry·L Tune, J T Coyle
Mar 1, 1980·Journal of Experimental Psychology. Human Learning and Memory·J G Snodgrass, M Vanderwart
Jan 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B VitielloT Sunderland

❮ Previous
Next ❯

Citations

Apr 13, 2011·Psychopharmacology·Rasha MechaeilJennifer Rusted
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Brian J Jones, Thomas P Blackburn
Jan 17, 2014·Experimental Brain Research·Mohammad SeyedabadiReza Rahimian
Sep 16, 2008·Schizophrenia Research·Shahin AkhondzadehSaeedeh Forghani
Apr 7, 2005·Brain Research Bulletin·Y LevkovitzS Fennig
Jul 29, 2009·Human Psychopharmacology·Ana L C ZaninottoSabine Pompéia
Jun 13, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·B VitálisL G Hársing
May 23, 2000·Annals of Medicine·M C BuhotL Segu
Oct 31, 2002·Human Psychopharmacology·Marie NaughtonBrian E. Leonard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aging Epidemiology

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.